BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

BACKGROUND: Although pazopanib treatment has become the standard chemotherapy in salvage setting for metastatic sarcoma patients, most patients progress after pazopanib treatment in 4 to 6 months. After failure to pazopanib, patients have limited options for treatment. Therefore, subsequent therapy...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Transl Oncol
Главные авторы: Kim, Hee Kyung, Kim, Sun Young, Lee, Su Jin, Kang, Mihyeon, Kim, Seung Tae, Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Lee, Dong Woo, Park, Woong Yang, Kim, Sung Joo, Park, Se Hoon, Lee, Jeeyun
Формат: Artigo
Язык:Inglês
Опубликовано: Neoplasia Press 2016
Предметы:
Original article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907899/
https://ncbi.nlm.nih.gov/pubmed/27267837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2016.03.008
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы